MedTrace Logo

Imaging of Cannabinoid 1 Receptors Using [11C]OMAR and PET

NCT01719497 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 74

Last updated 2022-07-13

No results posted yet for this study

Summary

The aim of the present study is to conduct a human trial of \[C-11\]OMAR, a new PET imaging agent for the brain cannabinoid type 1 receptors (CB1), to determine its pharmacokinetics and binding characteristics.

Conditions

  • Obesity
  • Alcohol Dependence
  • High Stress

Interventions

DRUG

[C-11]OMAR

PET radioligand

Sponsors & Collaborators

  • Yale University

    lead OTHER

Principal Investigators

  • Marc N Potenza, MD, PhD · Yale University

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2009-06-30
Primary Completion
2014-05-31
Completion
2014-05-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01719497 on ClinicalTrials.gov